|
US5800815A
(en)
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
|
US6309639B1
(en)
|
1991-02-05 |
2001-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
|
|
US5213796A
(en)
|
1991-05-06 |
1993-05-25 |
Dana Farber Cancer Institute |
Assay for polyomavirus in humans and uses thereof
|
|
US5578444A
(en)
|
1991-06-27 |
1996-11-26 |
Genelabs Technologies, Inc. |
Sequence-directed DNA-binding molecules compositions and methods
|
|
US5726014A
(en)
|
1991-06-27 |
1998-03-10 |
Genelabs Technologies, Inc. |
Screening assay for the detection of DNA-binding molecules
|
|
CA2135083C
(en)
|
1992-05-05 |
2004-01-06 |
Robert W. Chestnut |
Antibodies to p-selectin and their uses
|
|
US7910624B1
(en)
|
1995-03-03 |
2011-03-22 |
The Trustees Of Boston University |
Compositions for the treatment of blood disorders
|
|
AU696167B2
(en)
|
1993-10-29 |
1998-09-03 |
Trustees Of Boston University |
Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
|
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
|
US20020164575A1
(en)
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
|
US6780590B2
(en)
|
1999-09-14 |
2004-08-24 |
Sangamo Biosciences, Inc. |
Gene identification
|
|
CA2394850C
(en)
|
1999-12-06 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
|
IT1320168B1
(it)
|
2000-03-13 |
2003-11-18 |
Univ Ferrara |
Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
|
|
WO2001085765A2
(en)
|
2000-05-12 |
2001-11-15 |
Merck Patent Gmbh |
Identification of mfq-110, a human c2h2-type zinc finger protein
|
|
AU2002232536A1
(en)
|
2000-11-09 |
2002-05-21 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
|
AU2002219992A1
(en)
|
2000-12-01 |
2002-06-11 |
Sangamo Biosciences, Inc. |
Targeted regulation of gene expression
|
|
JP2005527180A
(ja)
|
2001-04-18 |
2005-09-15 |
プロテイン デザイン ラブス, インコーポレイテッド |
肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
|
|
EP2266396A3
(en)
|
2001-09-24 |
2011-06-15 |
Sangamo BioSciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
|
JP2006502748A
(ja)
|
2002-09-05 |
2006-01-26 |
カリフォルニア インスティテュート オブ テクノロジー |
遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
|
|
EP1581056B1
(en)
|
2002-12-13 |
2010-07-21 |
Genetix Pharmaceuticals Inc. |
Therapeutic retroviral vectors for gene therapy
|
|
WO2004098508A2
(en)
|
2003-04-30 |
2004-11-18 |
Napro Biotherapeutics, Inc. |
Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
DK2927318T3
(da)
|
2003-08-08 |
2020-08-03 |
Sangamo Therapeutics Inc |
Fremgangsmåde og sammensætninger til målrettet spaltning og rekombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
JP5059411B2
(ja)
|
2003-12-19 |
2012-10-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
短鎖干渉rnaの細胞トランスフェクティング処方物、関連する組成物および作製方法ならびに使用
|
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
|
WO2007014181A2
(en)
|
2005-07-25 |
2007-02-01 |
Johns Hopkins University |
Site-specific modification of the human genome using custom-designed zinc finger nucleases
|
|
ES2699273T3
(es)
|
2006-12-01 |
2019-02-08 |
Novartis Ag |
Anticuerpos anti-P-selectina y métodos de uso de los mismos para tratar enfermedades inflamatorias
|
|
US8945565B2
(en)
|
2006-12-01 |
2015-02-03 |
Selexys Pharmaceuticals Corporation |
Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
|
|
US20110212096A1
(en)
|
2006-12-01 |
2011-09-01 |
Scott Rollins |
Anti-p-selectin antibodies and methods of their use and identification
|
|
GB0713183D0
(en)
|
2007-07-06 |
2007-08-15 |
King S College London |
Method
|
|
EP3208339B1
(en)
|
2008-09-15 |
2019-05-01 |
The Children's Medical Center Corporation |
Modulation of bcl11a for treatment of hemoglobinopathies
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
KR101762466B1
(ko)
|
2009-12-23 |
2017-07-27 |
노파르티스 아게 |
지질, 지질 조성물 및 이의 사용 방법
|
|
WO2011103215A1
(en)
|
2010-02-16 |
2011-08-25 |
Mount Sinai School Of Medicine |
Embedded chimeric peptide nucleic acids and use thereof
|
|
WO2012075027A1
(en)
|
2010-11-29 |
2012-06-07 |
Mount Sinai School Of Medicine |
Embedded chimeric peptide nucleic acids for generation of induced pluripotent stem cells
|
|
BR112013000244A2
(pt)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipossomas com lipídeos apresentando pka vantajoso para administração de rna
|
|
US20140127814A1
(en)
|
2010-08-10 |
2014-05-08 |
Srinivasan Chandrasegaran |
Generation and use of pluripotent stem cells
|
|
WO2012031046A2
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Lipids suitable for liposomal delivery of protein-coding rna
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
EP2678339B1
(en)
|
2011-02-18 |
2016-07-13 |
Academia Sinica |
Methods and compositions for treating beta-thalassemia and sickle cell disease
|
|
DE202011050611U1
(de)
|
2011-07-01 |
2012-10-09 |
Makita Corporation |
Anordnung zum Bereitstellen eines Kraftstoff-Luftgemischs für eine Brennkraftmaschine
|
|
RU2014104090A
(ru)
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
WO2013019745A1
(en)
|
2011-07-29 |
2013-02-07 |
Georgia Health Sciences University |
Methods and compositions for genetically modifiying cells
|
|
US20140271657A1
(en)
|
2011-10-12 |
2014-09-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
|
CA2852672C
(en)
|
2011-10-17 |
2021-07-20 |
Massachusetts Institute Of Technology |
A microfluidic system and method for delivering a payload into a cell by causing perturbations in a cell membrane of the cell
|
|
US9394547B2
(en)
|
2012-01-03 |
2016-07-19 |
City University Of Hong Kong |
Method and apparatus for delivery of molecules to cells
|
|
US20130178421A1
(en)
|
2012-01-06 |
2013-07-11 |
Alcon Research, Ltd. |
Interfering rna delivery system and uses thereof
|
|
CN104144931B
(zh)
|
2012-01-27 |
2018-04-10 |
蒙特利尔大学 |
嘧啶并[4,5‑b]吲哚衍生物及其在造血干细胞的扩增中的应用
|
|
SG10201606959PA
(en)
|
2012-02-24 |
2016-09-29 |
Hutchinson Fred Cancer Res |
Compositions and methods for the treatment of hemoglobinopathies
|
|
DK2839013T3
(da)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
Ikke-disruptiv-gen-targetering
|
|
PT3241902T
(pt)
|
2012-05-25 |
2018-05-28 |
Univ California |
Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
|
|
WO2013176915A1
(en)
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
JP6279562B2
(ja)
|
2012-06-12 |
2018-02-14 |
ジェネンテック, インコーポレイテッド |
条件付きノックアウト対立遺伝子を生成するための方法および組成物
|
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
KR102530118B1
(ko)
|
2012-07-25 |
2023-05-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유도 dna 결합 단백질 및 게놈 교란 도구 및 이의 적용
|
|
CA2882499C
(en)
|
2012-08-29 |
2023-09-26 |
Sangamo Biosciences, Inc. |
Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
|
|
BR112015004522A2
(pt)
|
2012-09-04 |
2017-11-21 |
Cellectis |
receptor de antígeno quimérico multicadeia e usos destes
|
|
WO2014065596A1
(en)
|
2012-10-23 |
2014-05-01 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
WO2014085593A1
(en)
|
2012-11-27 |
2014-06-05 |
Children's Medical Center Corporation |
Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
|
|
CN108715602A
(zh)
|
2012-12-06 |
2018-10-30 |
西格马-奥尔德里奇有限责任公司 |
基于crispr的基因组修饰和调控
|
|
KR20150105634A
(ko)
|
2012-12-12 |
2015-09-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
DK2784162T3
(en)
|
2012-12-12 |
2015-07-13 |
Broad Inst Inc |
Design of systems, methods and optimized control manipulations for sequence manipulation
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
ES2553782T3
(es)
|
2012-12-12 |
2015-12-11 |
The Broad Institute, Inc. |
Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
|
|
DK3553174T3
(da)
|
2012-12-17 |
2025-08-04 |
Harvard College |
Rna-guided modificering af humant genom
|
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
|
EP3567104A1
(en)
|
2013-03-01 |
2019-11-13 |
Regents of the University of Minnesota |
Talen-based gene correction
|
|
WO2014136086A1
(en)
|
2013-03-08 |
2014-09-12 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
US10612043B2
(en)
|
2013-03-09 |
2020-04-07 |
Agilent Technologies, Inc. |
Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
|
|
NZ712727A
(en)
|
2013-03-14 |
2017-05-26 |
Caribou Biosciences Inc |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
WO2014150256A1
(en)
|
2013-03-15 |
2014-09-25 |
Global Blood Therapeutics, Inc. |
Compositions and methods for the modulation of hemoglobin (s)
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
PT2970948T
(pt)
|
2013-03-15 |
2019-03-20 |
Glaxosmithkline Biologicals Sa |
Métodos de purificação de arn
|
|
US20140273230A1
(en)
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
US11332719B2
(en)
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
EP3744842A1
(en)
|
2013-03-15 |
2020-12-02 |
The General Hospital Corporation |
Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
|
|
CA2908253C
(en)
|
2013-04-04 |
2024-01-09 |
Trustees Of Dartmouth College |
Compositions and methods for in vivo excision of hiv-1 proviral dna
|
|
US20150056629A1
(en)
|
2013-04-14 |
2015-02-26 |
Katriona Guthrie-Honea |
Compositions, systems, and methods for detecting a DNA sequence
|
|
WO2014172470A2
(en)
|
2013-04-16 |
2014-10-23 |
Whitehead Institute For Biomedical Research |
Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
|
|
RS63798B1
(sr)
|
2013-05-13 |
2022-12-30 |
Cellectis |
Cd19 specifični himerni antigenski receptor i njegove primene
|
|
EP2997133B1
(en)
|
2013-05-13 |
2023-08-23 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
DK3004352T3
(da)
|
2013-05-24 |
2017-11-27 |
Roche Innovation Ct Copenhagen As |
Oligonukleotidmodulatorer af b-celle-cll/lymfom 11a (bcl11a) og anvendelser deraf
|
|
EP3004337B1
(en)
|
2013-05-29 |
2017-08-02 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
AU2014273085B2
(en)
|
2013-05-29 |
2020-10-22 |
Cellectis |
New compact scaffold of Cas9 in the type II CRISPR system
|
|
MX385330B
(es)
|
2013-06-04 |
2025-03-18 |
Harvard College |
Regulación transcripcional guiada por ácido ribonucleico.
|
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
|
ES2987399T3
(es)
*
|
2013-06-05 |
2024-11-14 |
Univ Duke |
Edición génica guiada por ARN y regulación génica
|
|
US20150315252A1
(en)
|
2013-06-11 |
2015-11-05 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
|
JP6525971B2
(ja)
|
2013-06-11 |
2019-06-05 |
タカラ バイオ ユーエスエー, インコーポレイテッド |
タンパク質富化微細小胞、タンパク質富化微細小胞の作製方法及び使用方法
|
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
BR112015031611A2
(pt)
|
2013-06-17 |
2017-12-12 |
Massachusetts Inst Technology |
aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
|
|
AU2014281031B2
(en)
|
2013-06-17 |
2020-05-21 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
CN104239331B
(zh)
|
2013-06-19 |
2018-10-09 |
阿里巴巴集团控股有限公司 |
一种用于实现评论搜索引擎排序的方法和装置
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
WO2015006498A2
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
CN110819658B
(zh)
|
2013-07-10 |
2024-03-22 |
哈佛大学校长及研究员协会 |
用于RNA向导的基因调节和编辑的正交Cas9蛋白
|
|
PT3019619T
(pt)
|
2013-07-11 |
2021-11-11 |
Modernatx Inc |
Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
|
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
JP6502940B2
(ja)
|
2013-08-16 |
2019-04-17 |
マサチューセッツ インスティテュート オブ テクノロジー |
細胞への物質の選択的送達
|
|
MX2016002118A
(es)
|
2013-08-22 |
2016-06-28 |
Du Pont |
Modificacion del genoma de plantas por medio del uso de sistemas de ácido ribonucléico (arn) guía/ endonucleasa cas y metodos de uso.
|
|
GB201315321D0
(en)
|
2013-08-28 |
2013-10-09 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Transduction Buffer
|
|
US10760065B2
(en)
|
2013-09-05 |
2020-09-01 |
Massachusetts Institute Of Technology |
Tuning microbial populations with programmable nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
EP3842528A1
(en)
|
2013-09-18 |
2021-06-30 |
Kymab Limited |
Methods, cells and organisms
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
JP5774657B2
(ja)
|
2013-10-04 |
2015-09-09 |
国立大学法人京都大学 |
エレクトロポレーションを利用した哺乳類の遺伝子改変方法
|
|
WO2015052231A2
(en)
|
2013-10-08 |
2015-04-16 |
Technical University Of Denmark |
Multiplex editing system
|
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
US9850497B2
(en)
|
2013-11-04 |
2017-12-26 |
Regents Of The University Of Minnesota |
Gene targeting methods and tools
|
|
WO2015070083A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine,Inc. |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
|
EP3960856A1
(en)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
US20160298096A1
(en)
|
2013-11-18 |
2016-10-13 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
|
WO2015075195A1
(en)
|
2013-11-22 |
2015-05-28 |
Cellectis |
Method of engineering chemotherapy drug resistant t-cells for immunotherapy
|
|
EP3074515B1
(en)
|
2013-11-28 |
2018-11-14 |
Horizon Discovery Limited |
Somatic haploid human cell line
|
|
JP6793547B2
(ja)
*
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
|
KR20160097327A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유전자 산물, 구조 정보 및 유도성 모듈형 cas 효소의 발현의 변경을 위한 crispr-cas 시스템 및 방법
|
|
US9994831B2
(en)
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
MX374529B
(es)
|
2013-12-12 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
JP2017501149A
(ja)
|
2013-12-12 |
2017-01-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
粒子送達構成成分を用いた障害及び疾患の標的化のためのcrispr−cas系及び組成物の送達、使用及び治療適用
|
|
JP2017527256A
(ja)
|
2013-12-12 |
2017-09-21 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
HBV及びウイルス性疾患及び障害のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
MX2016007325A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
US20150191744A1
(en)
|
2013-12-17 |
2015-07-09 |
University Of Massachusetts |
Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
|
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
PL3083556T3
(pl)
|
2013-12-19 |
2020-06-29 |
Novartis Ag |
Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
|
|
AU2014368982B2
(en)
|
2013-12-19 |
2021-03-25 |
Amyris, Inc. |
Methods for genomic integration
|
|
KR20160102056A
(ko)
|
2013-12-26 |
2016-08-26 |
더 제너럴 하스피탈 코포레이션 |
멀티플렉스 가이드 rna
|
|
WO2015103153A1
(en)
|
2013-12-31 |
2015-07-09 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
|
JP6747974B2
(ja)
|
2014-01-08 |
2020-08-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Rna誘導型遺伝子ドライブ
|
|
CA2936646C
(en)
|
2014-01-24 |
2024-04-30 |
North Carolina State University |
Methods and compositions for sequences guiding cas9 targeting
|
|
DK3102673T3
(da)
|
2014-02-03 |
2020-07-06 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
|
|
US10287590B2
(en)
|
2014-02-12 |
2019-05-14 |
Dna2.0, Inc. |
Methods for generating libraries with co-varying regions of polynuleotides for genome modification
|
|
WO2015122967A1
(en)
|
2014-02-13 |
2015-08-20 |
Clontech Laboratories, Inc. |
Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
|
|
WO2015126927A2
(en)
|
2014-02-18 |
2015-08-27 |
Duke University |
Compositions for the inactivation of virus replication and methods of making and using the same
|
|
US11186843B2
(en)
|
2014-02-27 |
2021-11-30 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
|
EP3114227B1
(en)
|
2014-03-05 |
2021-07-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
|
AU2015234204A1
(en)
|
2014-03-20 |
2016-10-06 |
Universite Laval |
CRISPR-based methods and products for increasing frataxin levels and uses thereof
|
|
CN112964883A
(zh)
|
2014-03-24 |
2021-06-15 |
艾摩科诊断公司 |
用于全身性和非全身性自身免疫紊乱的改进的抗核抗体检测和诊断
|
|
CA2943622A1
(en)
|
2014-03-25 |
2015-10-01 |
Editas Medicine Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
WO2015148860A1
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
JP6695795B2
(ja)
|
2014-03-31 |
2020-05-20 |
株式会社サイエンス・ラスター |
造血細胞の増殖ペプチドおよびその用途
|
|
EP3126497B1
(en)
|
2014-04-01 |
2018-12-12 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
|
WO2015153791A1
(en)
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
|
|
EP3540061A1
(en)
|
2014-04-02 |
2019-09-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
WO2015153940A1
(en)
|
2014-04-03 |
2015-10-08 |
Massachusetts Institute Of Technology |
Methods and compositions for the production of guide rna
|
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
DK3132034T3
(da)
|
2014-04-14 |
2020-10-19 |
Nemesis Bioscience Ltd |
Terapeutikum
|
|
JP2017513485A
(ja)
|
2014-04-18 |
2017-06-01 |
エディタス・メディシン,インコーポレイテッド |
がん免疫療法のためのcrispr−cas関連方法、組成物および構成要素
|
|
EP3598984B1
(en)
|
2014-04-25 |
2024-04-10 |
The Children's Medical Center Corporation |
Compositions and methods to treating hemoglobinopathies
|
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
|
US10280419B2
(en)
|
2014-05-09 |
2019-05-07 |
UNIVERSITé LAVAL |
Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
|
|
US20170088819A1
(en)
|
2014-05-16 |
2017-03-30 |
Vrije Universiteit Brussel |
Genetic correction of myotonic dystrophy type 1
|
|
EP3152221A4
(en)
|
2014-05-20 |
2018-01-24 |
Regents of the University of Minnesota |
Method for editing a genetic sequence
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
CA2950173C
(en)
|
2014-06-06 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for modifying a targeted locus
|
|
WO2015191693A2
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
WO2015191911A2
(en)
|
2014-06-12 |
2015-12-17 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
|
ES2781323T3
(es)
|
2014-06-23 |
2020-09-01 |
Regeneron Pharma |
Montaje de ADN mediado por nucleasas
|
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
|
US20150376587A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
KR102386101B1
(ko)
|
2014-06-26 |
2022-04-14 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
|
|
US10017770B2
(en)
|
2014-07-03 |
2018-07-10 |
Ut-Battelle, Llc |
TNT cloning system
|
|
CA2954686A1
(en)
|
2014-07-11 |
2016-01-14 |
Pioneer Hi-Bred International, Inc. |
Agronomic trait modification using guide rna/cas endonuclease systems and methods of use
|
|
ES3047792T3
(en)
|
2014-07-14 |
2025-12-04 |
Univ California |
Crispr/cas transcriptional modulation
|
|
US10975406B2
(en)
|
2014-07-18 |
2021-04-13 |
Massachusetts Institute Of Technology |
Directed endonucleases for repeatable nucleic acid cleavage
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
AU2015311681B2
(en)
|
2014-09-04 |
2021-09-23 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
|
HUE055583T2
(hu)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
WO2016073990A2
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3237615B2
(en)
|
2014-12-24 |
2023-07-26 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
|
US20170369855A1
(en)
|
2014-12-24 |
2017-12-28 |
Dana-Farber Cancer Institute, Inc. |
Systems and methods for genome modification and regulation
|
|
CN107429263A
(zh)
|
2015-01-15 |
2017-12-01 |
斯坦福大学托管董事会 |
调控基因组编辑的方法
|
|
EP3247409B1
(en)
|
2015-01-21 |
2020-11-04 |
Cornell University |
Viral vectors for prophylaxis and therapy of hemoglobinopathies
|
|
WO2016118780A1
(en)
|
2015-01-21 |
2016-07-28 |
Fred Hutchinson Cancer Research Center |
Point-of-care and/or portable platform for gene therapy
|
|
HK1246690A1
(zh)
|
2015-01-21 |
2018-09-14 |
Sangamo Therapeutics, Inc. |
用於鉴定高度特异性核酸酶的方法和组合物
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
SG11201706766WA
(en)
*
|
2015-02-23 |
2017-09-28 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
EP3268044A2
(en)
|
2015-03-11 |
2018-01-17 |
The Broad Institute Inc. |
Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
|
|
US20180112213A1
(en)
|
2015-03-25 |
2018-04-26 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
EP3274453B1
(en)
|
2015-03-26 |
2021-01-27 |
Editas Medicine, Inc. |
Crispr/cas-mediated gene conversion
|
|
ES2764457T3
(es)
|
2015-03-31 |
2020-06-03 |
Glycotope Gmbh |
Vectores de expresión eucariotas que incluyen elementos reglamentarios de los grupos de genes de globina
|
|
ES2884838T3
(es)
|
2015-04-06 |
2021-12-13 |
Univ Leland Stanford Junior |
ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
EP3294873B2
(en)
|
2015-05-08 |
2024-09-18 |
The Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
|
US11390884B2
(en)
|
2015-05-11 |
2022-07-19 |
Editas Medicine, Inc. |
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
|
|
CA2984013A1
(en)
|
2015-05-12 |
2016-11-17 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2016201272A1
(en)
|
2015-06-12 |
2016-12-15 |
King Abdulaziz City For Science And Technology |
Method of diagnosing patients with conditions caused by mendelian mutations
|
|
CA2989831A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
EP3356520B1
(en)
|
2015-10-02 |
2022-03-23 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
|
EP3371306B8
(en)
|
2015-11-04 |
2023-02-22 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
|
SG11201805217XA
(en)
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
AU2017235333B2
(en)
*
|
2016-03-14 |
2023-08-24 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating beta hemoglobinopathies
|
|
AU2017252023B2
(en)
|
2016-04-18 |
2024-05-02 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
US20190345450A1
(en)
|
2016-06-17 |
2019-11-14 |
Fred Hutchinson Cancer Research Center |
Strategies to assess and/or produce cell populations with predictive engraftment potential
|
|
WO2018009506A1
(en)
|
2016-07-07 |
2018-01-11 |
St. Jude Children's Research Hospital |
Erythroid-specific promoter and method of use thereof
|
|
WO2018022619A1
(en)
|
2016-07-25 |
2018-02-01 |
Bluebird Bio, Inc. |
Bcl11a homing endonuclease variants, compositions, and methods of use
|
|
US20190169597A1
(en)
|
2016-08-19 |
2019-06-06 |
Bluebird Bio, Inc. |
Genome editing enhancers
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
LT3504229T
(lt)
|
2016-08-24 |
2021-12-10 |
Sangamo Therapeutics, Inc. |
Genų raiškos reguliavimas, panaudojant rekombinantines nukleazes
|
|
US20190203230A1
(en)
|
2016-09-28 |
2019-07-04 |
Novartis Ag |
Porous membrane-based macromolecule delivery system
|
|
TW201839136A
(zh)
*
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|